Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of iBio Inc (NASDAQ: IBIO) was $1.87 for the day, down -0.53% from the previous closing price of $1.88. In other words, the price has decreased by -$0.53 from its previous closing price. On the day, 0.87 million shares were traded. IBIO stock price reached its highest trading level at $1.985 during the session, while it also had its lowest trading level at $1.83.
Ratios:
Our analysis of IBIO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 8.39 and its Current Ratio is at 8.39. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In the most recent recommendation for this company, Oppenheimer on October 21, 2025, initiated with a Outperform rating and assigned the stock a target price of $5.
On October 17, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $2.
On May 28, 2024, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $5.Chardan Capital Markets initiated its Buy rating on May 28, 2024, with a $5 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 10 ’25 when Duran Felipe bought 9,191 shares for $2.72 per share. The transaction valued at 25,000 led to the insider holds 11,139 shares of the business.
Brenner Martin bought 9,191 shares of IBIO for $25,000 on Jan 10 ’25. The insider now owns 18,316 shares after completing the transaction at $2.72 per share. On Jan 10 ’25, another insider, Banjak Marc, who serves as the Chief Legal Officer of the company, bought 9,191 shares for $2.72 each. As a result, the insider paid 25,000 and bolstered with 11,066 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IBIO now has a Market Capitalization of 42051268 and an Enterprise Value of -4221734. For the stock, the TTM Price-to-Sale (P/S) ratio is 84.10 while its Price-to-Book (P/B) ratio in mrq is 0.68. Its current Enterprise Value per Revenue stands at -8.443 whereas that against EBITDA is 0.215.
Stock Price History:
The Beta on a monthly basis for IBIO is 1.20, which has changed by -0.23673469 over the last 52 weeks, in comparison to a change of 0.16098404 over the same period for the S&P500. Over the past 52 weeks, IBIO has reached a high of $6.89, while it has fallen to a 52-week low of $0.56. The 50-Day Moving Average of the stock is 30.56%, while the 200-Day Moving Average is calculated to be 43.26%.
Shares Statistics:
IBIO traded an average of 7.12M shares per day over the past three months and 3326480 shares per day over the past ten days. A total of 20.25M shares are outstanding, with a floating share count of 19.70M. Insiders hold about 12.38% of the company’s shares, while institutions hold 44.42% stake in the company. Shares short for IBIO as of 1765756800 were 3906126 with a Short Ratio of 0.55, compared to 1763078400 on 1174064. Therefore, it implies a Short% of Shares Outstanding of 3906126 and a Short% of Float of 17.57.
Earnings Estimates
A comprehensive evaluation of iBio Inc (IBIO) is underway, with the input of 3.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.04 and low estimates of -$0.08.
Analysts are recommending an EPS of between -$0.28 and -$0.29 for the fiscal current year, implying an average EPS of -$0.28. EPS for the following year is -$0.3, with 3.0 analysts recommending between -$0.18 and -$0.38.
Revenue Estimates
A total of 2 analysts have provided revenue estimates for IBIO’s current fiscal year. The highest revenue estimate was $500k, while the lowest revenue estimate was $100k, resulting in an average revenue estimate of $300k. In the same quarter a year ago, actual revenue was $400k
